Axiom Therapeutics
Discovering covalent drugs using ML-accelerated physics simulations to treat undruggable cancers.
Axiom’s foundational model predicts covalent drug interactions with cancer-causing proteins. They are currently piloting with biotechs and academic labs, and are advised by 4 world-leading scientists and commercial experts.
Founders
Ryan Geiser
CEO
Ryan is a Gates Scholar from the University of Cambridge, UK, who discovered new drugs during his PhD in Biophysical Chemistry. He then helped structure billon-dollar biopharma deals at Lazard.
Chris Haggard
CTO
Chris holds a PhD in Computational Chemistry from the University of Cambridge, UK, where he researched quantum simulation and ML methods for molecules, the core of Axiom’s technology.
Milestones
2024
Founded at Entrepreneur First